Despite intense efforts to develop ex vivo culture systems that support hemopoietic stem cell (HSC) expansion most if not all culture systems lead to loss rather than expansion of HSC. To obtain a net increase in HSC number or HSC expansion) symmetrical cell visions are needed, i.e. both daughter cells retain HSC characteristics. If one of the 2 daughter cells non net expansion of HSC will be seen. Lack of HSC expansion may therefore be due to HSC death (apoptosis), HSC commitment/differentiation, or insufficient HSC proliferation. We have developed an in vitro assay that can evaluate the fate of a single primitive hemopoietic progenitor capable of generating multiple daughter cells that can initiate long-term myeloid and lymphoid cultures, also determined Myeloid-Lymphoid-Initiating Cells of ML-IC. Using vital dyes, we have shown that ML-IC can undergo self-renewing cell divisions in vitro, therefore fulfilling the two minimal criteria of HSC, namely self-renewal and multi-lineage potential. Finally, we have shown that same conditions that support ML-IC growth also support high levels of Murine-Leukemia (MuL) viral gene transfer in ML-IC. This should now allow us to examine the mechanism underlying lack of ex vivo expansion of HSC. Specifically, we will assess the contribution of cell death, differentiation or poor proliferation to overall poor HSC expansion. This will be accomplished by evaluating the effect of over-expression of anti-apoptosis genes, genes that alter cell fate decision making processes, and genes that enhance cell proliferation on the number of repopulating cells. We will also determine the same division requirement for MuL virus and HIV based gene transfer in HSC. These studies will help to define optimal conditions for ex vivo HSC expansion and transduction. Finally, these studies will help to determine the relationship between in vitro defined stem cells, or ML-IC, and in vivo defined stem cells, or SRC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA065493-08
Application #
6652737
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-08-26
Project End
2003-05-31
Budget Start
Budget End
Support Year
8
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Romee, Rizwan; Cooley, Sarah; Berrien-Elliott, Melissa M et al. (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131:2515-2527
Stefanski, Heather E; Jonart, Leslie; Goren, Emily et al. (2018) A novel approach to improve immune effector responses post transplant by restoration of CCL21 expression. PLoS One 13:e0193461
Owen, David L; Mahmud, Shawn A; Vang, Kieng B et al. (2018) Identification of Cellular Sources of IL-2 Needed for Regulatory T Cell Development and Homeostasis. J Immunol 200:3926-3933
Osborn, Mark J; Lees, Christopher J; McElroy, Amber N et al. (2018) CRISPR/Cas9-Based Cellular Engineering for Targeted Gene Overexpression. Int J Mol Sci 19:
Oh, Felix; Todhunter, Deborah; Taras, Elizabeth et al. (2018) Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin. Clin Pharmacol 10:113-121
Rashidi, Armin; Ebadi, Maryam; Said, Bassil et al. (2018) Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. Am J Hematol :
Bejanyan, Nelli; Brunstein, Claudio G; Cao, Qing et al. (2018) Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv 2:909-922
Bachanova, Veronika; Sarhan, Dhifaf; DeFor, Todd E et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483-494
Xing, Yan; Smith, Michelle J; Goetz, Christine A et al. (2018) Thymic Epithelial Cell Support of Thymopoiesis Does Not Require Klotho. J Immunol 201:3320-3328
Prestipino, Alessandro; Emhardt, Alica J; Aumann, Konrad et al. (2018) Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med 10:

Showing the most recent 10 out of 395 publications